Dr Stephen Jamieson

BSc, MSc, PhD


Stephen Jamieson graduated from his PhD in cancer pharmacology in 2006 at The University of Auckland under the supervision of Prof. Mark McKeage. He then worked as a postdoctoral research scientist in the drug discovery laboratories at Cancer Research Technology Ltd in London, UK for 2 years, before taking up his current position at the ACSRC in late 2008. He is an associate investigator of the Maurice Wilkins Centre for Molecular Biodiscovery

Research | Current

My research is focussed on the preclinical development of novel anticancer drugs, utilising cell biology and pharmacology models of human cancer to progress novel anticancer drugs into clinical trials. My research has directly contributed to the entry into phase I clinical trials of the PI3-kinase inhibitor, PWT-33597, and the EGFR/HER2 inhibitor, PR-610.

Current drug discovery research projects include the development of small molecule inhibitors or prodrugs that selectively target:

  • Phosphoinositide 3-kinase
  • Perforin
  • Tumour hypoxia
  • Aldo keto reductase 1C3


Research group

Areas of expertise

  • Preclinical drug development
  • In vivo pharmacology
  • Patient derived xenografts
  • Preclinical tumour models
  • Drug pharmacokinetics

Selected publications and creative works (Research Outputs)

Contact details

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 0, Room 001
New Zealand